May 19, 2020/by ksmithAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
April 29, 2020/by ksmithAmplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
September 24, 2019/by eallisonAmplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
September 16, 2019/by eallisonAmplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
September 16, 2019/by eallisonAmplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
September 9, 2019/by eallisonFDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
April 12, 2019/by Lauren FishAmplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
February 11, 2019/by eallisonFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
November 12, 2018/by eallisonAmplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
June 7, 2018/by eallisonAmplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
June 5, 2018/by eallisonAmplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
April 30, 2018/by eallisonAmplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
March 19, 2018/by adminAmplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001
January 8, 2018/by adminAmplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference
January 5, 2017/by adminAmplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer
November 15, 2016/by adminFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
September 12, 2016/by adminAmplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
June 14, 2016/by adminAmplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
February 9, 2016/by adminAmplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
November 15, 2016/by adminFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
September 12, 2016/by adminAmplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
June 14, 2016/by adminAmplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
February 9, 2016/by adminAmplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
January 5, 2017/by adminAmplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer
November 12, 2018/by eallisonAmplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
June 7, 2018/by eallisonAmplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
June 5, 2018/by eallisonAmplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
April 30, 2018/by eallisonAmplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
March 19, 2018/by adminAmplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001
January 8, 2018/by adminAmplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference
September 24, 2019/by eallisonAmplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
September 16, 2019/by eallisonAmplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
September 16, 2019/by eallisonAmplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
September 9, 2019/by eallisonFDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
April 12, 2019/by Lauren FishAmplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
February 11, 2019/by eallisonFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
May 19, 2020/by ksmithAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
April 29, 2020/by ksmithAmplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
May 19, 2020/by ksmithAmplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
April 29, 2020/by ksmithAmplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
September 24, 2019/by eallisonAmplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
September 16, 2019/by eallisonAmplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
September 16, 2019/by eallisonAmplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
September 9, 2019/by eallisonFDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
April 12, 2019/by Lauren FishAmplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
February 11, 2019/by eallisonFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
November 12, 2018/by eallisonAmplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
June 7, 2018/by eallisonAmplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
June 5, 2018/by eallisonAmplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
April 30, 2018/by eallisonAmplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
March 19, 2018/by adminAmplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001
January 8, 2018/by adminAmplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference
January 5, 2017/by adminAmplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer
November 15, 2016/by adminFDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
September 12, 2016/by adminAmplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections
June 14, 2016/by adminAmplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections
February 9, 2016/by adminAmplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
